Group 1 - The core viewpoint of the news is that CloudTop New Horizon has signed two strategic cooperation agreements with Haisen Biopharmaceutical, which will enhance operational efficiency and commercial capabilities in the cardiovascular disease sector [1][2] - The commercialization service agreement allows CloudTop New Horizon to provide services for six mature products from Haisen Biopharmaceutical, with service fees ranging from 20% to 55% of the quarterly net sales [1] - The annual transaction caps for Haisen Biopharmaceutical are set at RMB 560 million for 2026, RMB 616 million for 2027, and RMB 677 million for 2028 [1] Group 2 - The licensing agreement grants CloudTop New Horizon exclusive rights to develop, register, and commercialize Lerodalcibep in Greater China, enhancing its late-stage pipeline [2] - An initial payment of approximately RMB 205 million will be made by CloudTop New Horizon, along with potential milestone payments totaling up to RMB 2.12 billion for development and regulatory milestones, and up to RMB 19.77 billion for sales milestones [2] - Lerodalcibep is a third-generation PCSK9 inhibitor developed by LIB Therapeutics, aimed at lowering LDL-C levels in patients with high cholesterol [2]